An interventional study of (18)F]fluoroethoxybenzovesamicol ([(18)F (FEOBV) PET and Dihydrotetrabenazine (DTBZ) PET in Parkinson Disease and Progressive Supranuclear Palsy, sponsored by University of Michigan. Active, not recruiting at 1 site in United States. Open to participants aged 21 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-07-27.
Sponsored by University of Michigan · Not applicable, Interventional, and Basic science
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 23 studies in Parkinson Disease by University of Michigan — 3 open to participants now, 4 under way, none of them phase 3. Parkinson Disease · University of Michigan.
Among the 23 studies in Parkinson Disease by University of Michigan, this one has the largest planned enrollment of the 15 interventional ones that give a count, is one of 2 that started in 2022, is one of 9 with no phase, and was the 15th registered.
4,583 studies on the registry are indexed under Parkinson Disease; 1,086 are open to participants now.
Browse Parkinson Disease studies →3 of the 23 studies in Parkinson Disease by University of Michigan are open now, in 1 country. Recruiting first, the newest first:
University of Michigan · Sites in United States
Ages 50+
University of Michigan · Sites in United States
Ages 45+
University of Michigan · Sites in United States
Ages 45–90
By country, each count listing its studies:
Of the 752 Parkinson Disease studies recruiting now, 314 (42%) set no upper age limit and 127 (17%) stop at 75 or younger; 64 take children under 18; 189 take healthy volunteers.
This study: 21 Years and older · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
23 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 4 · Phase 4 1
First in 2006; this study’s year is marked. 2 started in 2022.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 125 is above the median of 40 across 3,360 interventional studies indexed under Parkinson Disease.
Median enrollment 25 across the 15 interventional studies, 74 across the 8 observational. Of the 19 that completed or were terminated, 7 (37%) have results posted.
This tab as a report to print or save as PDF → With an account.
University of Michigan is the lead sponsor of 1,509 studies on the registry; 194 are open to participants now.
Of its 170 completed or terminated interventional studies of FDA-regulated products, 134 (79%) have results posted.
3 of the studies in Parkinson Disease by University of Michigan that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07543861University of MichiganA Pilot Study of In-lab Dynamic Standing in Parkinson's Disease | 2027-03 |
| NCT07642908University of MichiganStriatal and Extra-Striatal Cholinergic Terminal Density in LRRK2-PD Mutation | 2027-04-01 |
| NCT05459753University of MichiganCholinergic Mechanisms of Attentional-motor Integration and Gait Dysfunction in Parkinson Disease (UDALL) | 2027-06-30 |
Add all 3 to your calendar (.ics) → With an account.
Among the 23 studies in Parkinson Disease by University of Michigan, from their registry updates:
This tab as a report to print or save as PDF → With an account.
To perform a prospective cohort study with [(18)F]fluoroethoxybenzovesamicol (FEOBV) brain PET at baseline and 2-year follow-up in PD subjects at risk of conversion to non-episodic and episodic (falls and FoG) PIGD motor features and cognitive changes at the same time points.
Postural instability and gait difficulty (PIGD) motor and cognitive changer features are common in Parkinson disease (PD), and a significant cause of treatment-refractory disability. Accumulating evidence implicates cholinergic systems dysfunctions as significant contributors to gait and balance and cognitive impairment. During the initial funding period, the investigators established the vesicular acetylcholine transporter (VAChT) ligand FEOBV, which uniquely assesses cholinergic terminal density in high density regions such as the striatum. Recent cross-sectional findings suggest that people with Parkinson's (PwP) participants with isolated falls and those with freezing of gait (FoG) status share common cholinergic deficits in the thalamus (lateral geniculate nucleus (LGN)) and striatum (caudate) with more extensive striatal, limbic, and prefrontal VAChT reductions in PwP with FoG. These data suggest that SChI deficits are a common denominator in the etiology of falls and FoG. These results emphasize the need to understand PIGD, falls, and FoG as products of cholinergic projection dysfunctions within the framework of failing Attentional-Motor Integration (AMI) combined with failures of additional multisensory and cognitive integration.
There is novel preliminary data that cholinergic deficits of the medial geniculate nucleus (MGN) and the entorhinal cortex (ERC) are robustly associated with non-episodic PIGD deficits. These results imply a significant role of impaired sensorimotor integration underlying non-episodic PIGD motor features in PwP. There is also have novel data that cholinergic changes in the cingulo-opercular task control network (COTC) are a robust correlate of cognitive changes in PwP. The overarching goal of this project is to investigate the evolution of cholinergic deficits within multisensory, cognitive and motor integration brain regions and development of PIGD features and cognitive deficits in PwP. This study will perform a prospective cohort study with FEOBV brain PET at baseline and 2-year follow-up.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Individuals with idiopathic Parkinson's disease.
Radiation: (18)F]fluoroethoxybenzovesamicol ([(18)F (FEOBV) PET · Radiation: Dihydrotetrabenazine (DTBZ) PET
Participants will receive an injection of 8 mCi \[18F\]FEOBV PET tracer and undergo a CT of the head.
Participants will receive an injection of 15 mCi \[11C\]DTBZ PET tracer and undergo a CT of the head.
Interval change on the Unified Parkinson's disease rating scale (UPDRS) motor rating scale over a 2-yr period
Interval change baseline vs 2-yr follow-up on the UPDRS motor score. UPDRS motor section is scored from 0-132, with higher scores indicating more severe motor symptoms.
Time frame: At Baseline and at 2-year follow up
Cholinergic brain PET FEOBV PET distribution volume ratio (DVR) interval change over a 2-yr period
Interval change baseline vs 2-yr follow in cholinergic brain FEOBV PET DVR
Time frame: At Baseline and at 2-year follow up
Cognitive 2-yr interval change on the Montreal Cognitive Assessment (MoCa) cognitive scale
Interval change baseline vs 2-yr follow-up on the Montreal Cognitive Assessment (MoCa) cognitive scale. The MoCa is scored out of 30, with higher scores indicating better cognition.
Time frame: At Baseline and at 2-year follow up
Started Mar 2022 (actual). Primary completion is estimated for Jun 2027, 63 months after the start.
Of 1,297 non-industry interventional studies with no phase under Parkinson Disease, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 44. This study's planned 63 months is above that.
Counting every sponsor, half of 1,373 studies reached it within 25 months; a quarter within 11 and three quarters within 44.
How these figures are worked out, and which studies are left out of them.
This study is active, not recruiting, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.